Idiopathic Pulmonary Fibrosis Clinical Trials in Kansas City, Kansas

5 studies are recruiting for idiopathic pulmonary fibrosis in Kansas City, Kansas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

    This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted value and fibrosis of 20% or more confirmed by a high-resolution comp…

    Stage
    Phase 2
    Ages
    40 and older
    Site
    University of Kansas Medical Center, Kansas City, Kansas
    Locations
    46 in total
    Run by
    Boehringer Ingelheim

    See if you can join NCT07036523 on ClinicalTrials.gov

  2. Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

    Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.

    Stage
    Phase 2
    Ages
    40 and older
    Site
    University of Kansas, Kansas City, Kansas
    Locations
    20 in total
    Run by
    Cumberland Pharmaceuticals

    See if you can join NCT05571059 on ClinicalTrials.gov

  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

    This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with …

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Kansas Medical Center, Kansas City, Kansas
    Locations
    373 in total
    Run by
    Boehringer Ingelheim

    See if you can join NCT06238622 on ClinicalTrials.gov

  4. WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

    Stage
    Phase 2
    Ages
    40 and older
    Site
    WISPer site in Kansas City, KS, Kansas City, Kansas
    Locations
    71 in total
    Run by
    Mediar Therapeutics

    See if you can join NCT06967805 on ClinicalTrials.gov

  5. Interstitial Lung Disease Research Unit Biobank

    Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.

    Stage
    Not phased
    Ages
    18 and older
    Site
    The University of Kansas Medical Center, Kansas City, Kansas
    Run by
    University of Kansas Medical Center

    See if you can join NCT05392881 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.